Skip to main content
Discure Technologies Ltd logo

Discure Technologies Ltd

Petah Tikva, IsraelSee on the mapFounded 2019

  • Neuromodulation
  • Series A

Discure Technologies Ltd develops minimally invasive bioelectronic solutions for spinal and synovial joint conditions, with a focus on degenerative disc disease and low back pain. Its implantable disc regeneration system is designed to restore disc fluid dynamics and support tissue healing, and is being evaluated in clinical trials in Europe and North America.

Raised
$27M
Aug 2025
Series A
Investors
6
Founded
2019
Employees
11–50

reccy insights

Recent highlights

Discure’s most concrete dated milestones in the available company information are its financing events: a Seed round on Apr 11, 2022, MedTech Innovator non-equity assistance dated Jun 7, 2022, and a $11 million Series A recorded on Sep 10, 2024. A separate financing signal lists a $16 million Series A dated Aug 14, 2025, with BOLD Capital Partners, Supernova Invest, Sanara Capital, multiple US hospital networks, and leading orthopedic surgeons identified as lead investors. The company is developing an implantable bioelectronic system intended to address degenerative disc disease by supporting fluid, oxygen, and nutrient movement within the disc. Its system is described as being evaluated in clinical trials in Europe and North America. Discure has also received FDA Breakthrough Device designation and recognition in spine-care and health technology competitions; the available details do not specify dates or award names.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes Discure Technologies Ltd distinct

  1. 01Targets disc degeneration itself rather than focusing only on back-pain symptoms.
  2. 02Designed as a minimally invasive outpatient procedure without hospitalization or rehabilitation.
  3. 03The disc regeneration system is reported to be in clinical evaluation in Europe and North America.
  4. 04The company has received FDA Breakthrough Device designation and recognition in spine-care and health technology competitions.

Technology & products

  • Disc regeneration system

    An implantable bioelectronic device designed to support disc fluid dynamics and tissue healing for degenerative disc disease.

  • Minimally invasive implantable bioelectronic device for degenerative disc disease.
  • Disc regeneration system designed to restore healthy fluid dynamics, cushioning, and spinal stability.

Funding

$27M disclosed
6 investors

Investors6

Also backed by
  • Sanara Capital
  • multiple US hospital networks
  • leading orthopedic surgeons

Similar companies

About Discure Technologies Ltd

Products
Disc regeneration system
Focus areas
Medical devices, bioelectronics, spinal health, degenerative disc disease, back pain, minimally invasive treatment, disc regeneration, clinical trials
Headquarters
Petah Tikva, Israel
Founded
2019
Employees
11–50
Status
Active · private